Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | PIM1 | P11309 | 3/20 | 0.47 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29860539 | 0.84 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2KDM4EHPGD | |
| SCHEMBL351486 | 0.84 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2KDM4EHPGD | |
| SCHEMBL4101721 | 0.83 | ALDH1A1 (0.56) | ALDH1A1MAPTSMN1; SMN2KDM4EHPGD | |
| SCHEMBL28384025 | 0.82 | ALDH1A1 (0.95) | ALDH1A1MAPTSMN1; SMN2KDM4EHPGD | |
| SCHEMBL12630186 | 0.82 | MAPT (0.54) | ALDH1A1MAPTSMN1; SMN2KDM4EHPGD | |
| SCHEMBL28296154 | 0.79 | ALDH1A1 (0.79) | ALDH1A1MAPTSMN1; SMN2KDM4EHPGD | |
| SCHEMBL9319003 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MAPTSMN1; SMN2KDM4EHPGD | |
| SCHEMBL12663994 | 0.77 | MAPT (0.48) | ALDH1A1MAPTSMN1; SMN2KDM4EHPGD | |
| SCHEMBL42617 | 0.77 | ALDH1A1 (0.75) | ALDH1A1MAPTSMN1; SMN2KDM4EHPGD | |
| SCHEMBL588905 | 0.77 | TDP1 (0.44) | ALDH1A1MAPTSMN1; SMN2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104703979-B | Heterocyclic compounds and their use | 无限药品股份有限公司 | 2018-11-27 | — | — | CN | disclosed |
| US-20160207940-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2016-07-21 | — | — | US | disclosed |
| US-20160207940-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2016-07-21 | — | — | US | disclosed |
| US-20160207940-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2016-07-21 | — | — | US | disclosed |
| US-9255108-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-9255108-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| EP-2947082-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | Pfizer Inc (US) | 2015-11-25 | — | — | EP | disclosed |
| US-9139587-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2676958-B1 | N1-Pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER (US) | 2015-07-01 | — | — | EP | disclosed |
| CN-104703979-A | Heterocyclic compounds and their use | INFINITY PHARMACEUTICALS INC | 2015-06-10 | — | — | CN | disclosed |
| EP-1715867-A4 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080292626-A1 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-11-27 | — | — | US | disclosed |
| US-20080292626-A1 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-11-27 | — | — | US | disclosed |
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| CN-1933838-A | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK & CO INC (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1715867-A1 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005079802-A1 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-6875764-B1 | Urea and thiourea compounds useful for treatment of coccidiosis | NEW PHARMA RESEARCH SWEDEN AB (SE) | 2005-04-05 | — | — | US | disclosed |
| EP-1224165-A1 | NOVEL COMPOUNDS | New Pharma Research Sweden AB (SE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001030749-A1 | NOVEL COMPOUNDS | NEW PHARMA RESEARCH SWEDEN AB (SE) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GABRA5 | ALDH1A1 1569/4885MAPT 449/4885SMN1; SMN2 3565/4885 |
| US-20160207940-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3154/4885MAPT 1605/4885SMN1; SMN2 1464/4885 |
| US-20080292626-A1 | KINESIN INHIBITORS | KIF5B, KIF5A, KIF5C | ALDH1A1 1978/4885MAPT 38/4885SMN1; SMN2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.